On Friday, January 10, 2025, Cathie Wood‘s Ark Invest executed significant trades, focusing heavily on the biotech and pharmaceuticals sectors. The investment firm sold shares of Adaptive Biotechnologies Corp while making sizable purchases in Illumina Inc and Intellia Therapeutics Inc.
The Illumina Trade saw Ark Invest’s ARKG and ARKK funds collectively purchase 15,463 shares of Illumina Inc.
With Illumina’s stock closing at $136.69, the total investment amounted to approximately $2.1 million.
Illumina, known for its DNA sequencing technology, continues to be a key player in the genomics revolution, making it an attractive choice for Ark’s growth-focused strategy.
The Intellia Therapeutics Trade involved Ark Invest acquiring a total of 166,302 shares across its ARKG and ARKK funds. The purchase, valued at roughly $1.7 million based on a closing price of $10.20 per share, signifies Ark’s confidence in Intellia’s potential in the CRISPR gene-editing space. Intellia’s recent developments in therapeutic applications have positioned it as a leader in genetic medicine.
Other Key Trades:
- Adaptive Biotechnologies Corp: Ark Invest’s ARKG fund sold 130,790 shares, valued at around $850,000, based on a closing price of $6.50.
- Recursion Pharmaceuticals Inc: The ARKK fund bought 264,596 shares, worth approximately $1.8 million, with a closing price of $6.88.
- Cloudflare Inc: Ark’s ARKW fund divested 7,840 shares, valued at about $880,000, given the closing price of $112.62.